Inês Brás Marques
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Inês Brás Marques has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Lívia Sousa
Universidade Federal do Pará, Brazil
8 shared publications - Inês Correia
Neurology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
6 shared publications - Sónia Batista
Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
5 shared publications Rogério Ferreira
Internal Medicine Department, Centro Hospitalar e Universitário de Coimbra, Praceta Prof. Mota Pinto, 3000-075 Coimbra, Portugal
3 shared publications- Ana Inês Martins
Neurology Department, Coimbra University Hospital Centre, Coimbra, Portugal
2 shared publications Carmo Macário
Department of Neurology (AMN, SB, CM, IS, LS, LC), Centro Hospitalar e Universitário de Coimbra; Visual Neuroscience Laboratory and Centre for Neuroscience and Cell Biology, Institute for Biomedical Imaging and Life Sciences (IBILI) (CA, OCd, IS, MC-B), Faculty of Medicine (SB, IS, LS, LC), and Institute for Nuclear Sciences Applied to Health (ICNAS) (CA, OCd, IS, MC-B), University of Coimbra; and Department of Neurology (IBM), Hospital da Luz, Lisbon, Portugal
2 shared publications
Latest Publications
- 16 September 2026
- Published by Taylor & Francis in Applied Neuropsychology: Adult
- p. 1-9
Longitudinal changes in social cognition in early relapsing-remitting multiple sclerosis over two years
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system, and is one of the leading causes of neurologic disability in young adults (Browne et a...
- 16 September 2026
- Published by Taylor & Francis in Applied Neuropsychology: Adult
- p. 1-9
Longitudinal changes in social cognition in early relapsing-remitting multiple sclerosis over two years
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system, and is one of the leading causes of neurologic disability in young adults (Browne et a...
- Open Access
- 16 July 2025
- Published by Consortium of Multiple Sclerosis Centers in International Journal of MS Care
- Vol. 27 (Q3) , 173-178
Apathy in Early Relapsing-Remitting Multiple Sclerosis: Prevalence and Predictors
Background: Apathy, a neuropsychiatric symptom characterized by a lack of motivation and affecting cognitive, emotional, and behavioral domains, is being increasingly recognized in multiple sclerosis (MS), with an estimated prevalence of 19% to 43%. However, apathy remains underinvestigated in early MS. In this study, we aim to evaluate apathy in people with relapsing-remitting MS (RRMS) whose disease duration has been less than 5 years. Methods: The study included 38 people with RRMS with a disease duration of less than 5 years and 38 matched controls. Clinical and comprehensive neuropsychological evaluations were performed. Apathy was evaluated using the Apathy Evaluation Scale, Clinician Version (AES-C). Depressive symptoms, anxiety, fatigue, and quality of life were also assessed. Results: Apathy prevalence was 42.1%. Apathy scores correlated with depressive symptoms, anxiety, fatigue, lower quality of life, younger age, and worse performance in frontal lobe tests (Trail Making Test-A [TMT-A] and Symbol Digit Modalities Test). Independent apathy predictors were depressive symptoms (OR, 4.05; 95% CI, 1.22-13.5; P = .023), global quality of life (OR, 1.7; 95% CI, 1.08-2.64; P = .021), and TMT-A score (OR, 1.14; 95% CI, 1.02-1.27; P = .020). Conclusions: Apathy is a disabling symptom that is present in a significant percentage of people in the first years after they have been diagnosed with RRMS. Thus, people with MS should should be routinely screened for apathy, and symptoms should be managed when it occurs. We identified depressive symptoms, low quality of life, and executive dysfunction as predictors of apathy in this population.
- 16 July 2025
- Published by Consortium of Multiple Sclerosis Centers in International Journal of MS Care
- Vol. 27 (Q3) , 173-178
Open AccessApathy in Early Relapsing-Remitting Multiple Sclerosis: Prevalence and Predictors
Background: Apathy, a neuropsychiatric symptom characterized by a lack of motivation and affecting cognitive, emotional, and behavioral domains, is being increasingly recognized in multiple sclerosis (MS), with an estimated prevalence of 19% to 43%. However, apathy remains underinvestigated in early MS. In this study, we aim to evaluate apathy in people with relapsing-remitting MS (RRMS) whose disease duration has been less than 5 years. Methods: The study included 38 people with RRMS with a disease duration of less than 5 years and 38 matched controls. Clinical and comprehensive neuropsychological evaluations were performed. Apathy was evaluated using the Apathy Evaluation Scale, Clinician Version (AES-C). Depressive symptoms, anxiety, fatigue, and quality of life were also assessed. Results: Apathy prevalence was 42.1%. Apathy scores correlated with depressive symptoms, anxiety, fatigue, lower quality of life, younger age, and worse performance in frontal lobe tests (Trail Making Test-A [TMT-A] and Symbol Digit Modalities Test). Independent apathy predictors were depressive symptoms (OR, 4.05; 95% CI, 1.22-13.5; P = .023), global quality of life (OR, 1.7; 95% CI, 1.08-2.64; P = .021), and TMT-A score (OR, 1.14; 95% CI, 1.02-1.27; P = .020). Conclusions: Apathy is a disabling symptom that is present in a significant percentage of people in the first years after they have been diagnosed with RRMS. Thus, people with MS should should be routinely screened for apathy, and symptoms should be managed when it occurs. We identified depressive symptoms, low quality of life, and executive dysfunction as predictors of apathy in this population.
- Open Access
- 1 February 2019
- Published by Ordem dos Medicos in Acta Medica Portuguesa
- Vol. 32 (1) , 81-85
Vaccination Controversies: An Adult Case of Post-Vaccinal Acute Disseminated Encephalomyelitis
Acute disseminated encephalomyelitis is a rare inflammatory demyelinating multifocal disease of the central nervous system that typically occurs in children following vaccination or exanthematous viral infections and conveys an elevated risk of neurological sequelae unless promptly recognized and treated. We describe an adult case of acute disseminated encephalomyelitis following vaccination against Mumps, Measles and Rubella, presenting with fever and progressive neurological deficits which improved under systemic corticosteroid therapy. Considering the ongoing public debate regarding universal vaccination and the surge of previously controlled infectious diseases, we aim not only to underline the need for a rigorous assessment of vaccination safety on adult patients in order to prevent misguidance of public opinion, but also to alert clinicians for an early diagnosis of acute disseminated encephalomyelitis in these patients, the incidence of which we speculate may be rising.
- 1 February 2019
- Published by Ordem dos Medicos in Acta Medica Portuguesa
- Vol. 32 (1) , 81-85
Open AccessVaccination Controversies: An Adult Case of Post-Vaccinal Acute Disseminated Encephalomyelitis
Acute disseminated encephalomyelitis is a rare inflammatory demyelinating multifocal disease of the central nervous system that typically occurs in children following vaccination or exanthematous viral infections and conveys an elevated risk of neurological sequelae unless promptly recognized and treated. We describe an adult case of acute disseminated encephalomyelitis following vaccination against Mumps, Measles and Rubella, presenting with fever and progressive neurological deficits which improved under systemic corticosteroid therapy. Considering the ongoing public debate regarding universal vaccination and the surge of previously controlled infectious diseases, we aim not only to underline the need for a rigorous assessment of vaccination safety on adult patients in order to prevent misguidance of public opinion, but also to alert clinicians for an early diagnosis of acute disseminated encephalomyelitis in these patients, the incidence of which we speculate may be rising.
- 1 December 2018
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 8 (6) , 492-500
The neural basis of fatigue in multiple sclerosis
Background Fatigue is a frequent disabling symptom in multiple sclerosis (MS), but its pathophysiology remains incompletely understood. This study aimed to explore the underlying neural basis of fatigue in patients with MS. Methods We enrolled 60 consecutive patients with MS and 60 healthy controls (HC) matched on age, sex, and education. Fatigue was assessed using the Portuguese version of the Modified Fatigue Impact Scale (MFIS). All participants underwent 3T brain MRI (conventional and diffusion tensor imaging [DTI] sequences). White matter (WM) focal lesions were identified and T1/T2 lesion volumes were computed. Tract-based spatial statistics were applied for voxel-wise analysis of DTI metrics fractional anisotropy and mean diffusivity (MD) on normal-appearing WM (NAWM). Using Freesurfer software, total and regional volumes of cortical and subcortical gray matter (GM) were calculated. Results Compared to HC, patients with MS scored significantly higher on MFIS (33.8 ± 19.7 vs 16.5 ± 15.1, p < 0.001). MFIS scores were not significantly correlated with T1/T2 lesion volumes, total GM volume, or any regional volume of cortical and subcortical GM. Significant correlations were found between global scores of MFIS and MD increase of the NAWM skeleton, including corona radiata, internal capsule, external capsule, corticospinal tract, cingulum, corpus callosum, fornix, superior longitudinal fasciculus, superior fronto-occipital fasciculus, sagittal stratum, posterior thalamic radiation, cerebral peduncle, and uncinate fasciculus. Conclusions In this study, fatigue was associated with widespread NAWM damage but not with lesion load or GM atrophy. Functional disconnection, caused by diffuse microstructural WM damage, might be the main neural basis of fatigue in MS.
- 1 December 2018
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 8 (6) , 492-500
The neural basis of fatigue in multiple sclerosis
Background Fatigue is a frequent disabling symptom in multiple sclerosis (MS), but its pathophysiology remains incompletely understood. This study aimed to explore the underlying neural basis of fatigue in patients with MS. Methods We enrolled 60 consecutive patients with MS and 60 healthy controls (HC) matched on age, sex, and education. Fatigue was assessed using the Portuguese version of the Modified Fatigue Impact Scale (MFIS). All participants underwent 3T brain MRI (conventional and diffusion tensor imaging [DTI] sequences). White matter (WM) focal lesions were identified and T1/T2 lesion volumes were computed. Tract-based spatial statistics were applied for voxel-wise analysis of DTI metrics fractional anisotropy and mean diffusivity (MD) on normal-appearing WM (NAWM). Using Freesurfer software, total and regional volumes of cortical and subcortical gray matter (GM) were calculated. Results Compared to HC, patients with MS scored significantly higher on MFIS (33.8 ± 19.7 vs 16.5 ± 15.1, p < 0.001). MFIS scores were not significantly correlated with T1/T2 lesion volumes, total GM volume, or any regional volume of cortical and subcortical GM. Significant correlations were found between global scores of MFIS and MD increase of the NAWM skeleton, including corona radiata, internal capsule, external capsule, corticospinal tract, cingulum, corpus callosum, fornix, superior longitudinal fasciculus, superior fronto-occipital fasciculus, sagittal stratum, posterior thalamic radiation, cerebral peduncle, and uncinate fasciculus. Conclusions In this study, fatigue was associated with widespread NAWM damage but not with lesion load or GM atrophy. Functional disconnection, caused by diffuse microstructural WM damage, might be the main neural basis of fatigue in MS.
- 1 July 2018
- Published by Wolters Kluwer Health in The Neurologist
- Vol. 23 (4) , 131-134
Myelitis and Polyradiculoneuropathy With Severe Pain
Brucellosis, an endemic zoonosis in Portugal, is a multisystem disease, presenting with neurological manifestations in up to 25% of cases. Neurobrucellosis diagnostic criteria include evidence of central nervous system invasion, either by documenting increased blood-brain barrier permeability that normalizes after treatment or by Brucella isolation. We report 2 patients with systemic brucellosis presenting with neurological symptoms: A 28-year-old female with progressive hemiparesis associated with severe refractory thoracic and lumbar pain, whose spinal magnetic resonance imaging identified longitudinally extensive myelitis. Brucella agglutination test was positive in blood; however, cerebrospinal fluid cytochemical, serological testing, and cultures were negative. A 58-year-old male with intermittent fever in the evening, associated with severe refractory cervical and lumbar spinal and radicular pain. Blood workup identified leukocytosis, elevated inflammatory markers and positive Brucella agglutination test. Cerebrospinal fluid presented mild protein increase and negative serological testing and cultures. Electromyogram revealed demyelinating polyradiculoneuropathy. In both cases, antibiotic therapy induced symptom resolution. Despite the neurological presentation, no evidence of direct nervous system infection was found. An indirect mechanism appears to be involved, such as a parainfectious syndrome or circulating endotoxins release by the bacteria. Brucellosis should be considered in patients presenting with inflammatory neurological symptoms in endemic regions. Prompt diagnosis and treatment are important as chronic infection has significant morbidity.
- 1 July 2018
- Published by Wolters Kluwer Health in The Neurologist
- Vol. 23 (4) , 131-134
Myelitis and Polyradiculoneuropathy With Severe Pain
Brucellosis, an endemic zoonosis in Portugal, is a multisystem disease, presenting with neurological manifestations in up to 25% of cases. Neurobrucellosis diagnostic criteria include evidence of central nervous system invasion, either by documenting increased blood-brain barrier permeability that normalizes after treatment or by Brucella isolation. We report 2 patients with systemic brucellosis presenting with neurological symptoms: A 28-year-old female with progressive hemiparesis associated with severe refractory thoracic and lumbar pain, whose spinal magnetic resonance imaging identified longitudinally extensive myelitis. Brucella agglutination test was positive in blood; however, cerebrospinal fluid cytochemical, serological testing, and cultures were negative. A 58-year-old male with intermittent fever in the evening, associated with severe refractory cervical and lumbar spinal and radicular pain. Blood workup identified leukocytosis, elevated inflammatory markers and positive Brucella agglutination test. Cerebrospinal fluid presented mild protein increase and negative serological testing and cultures. Electromyogram revealed demyelinating polyradiculoneuropathy. In both cases, antibiotic therapy induced symptom resolution. Despite the neurological presentation, no evidence of direct nervous system infection was found. An indirect mechanism appears to be involved, such as a parainfectious syndrome or circulating endotoxins release by the bacteria. Brucellosis should be considered in patients presenting with inflammatory neurological symptoms in endemic regions. Prompt diagnosis and treatment are important as chronic infection has significant morbidity.
- 1 October 2017
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 17, 63-68
Pregnancy in Multiple Sclerosis: A Portuguese cohort study
- 1 October 2017
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 17, 63-68
Pregnancy in Multiple Sclerosis: A Portuguese cohort study
- 1 May 2017
- Published by Elsevier in International Immunopharmacology
- Vol. 46, 105-111
Long-term effectiveness and safety of natalizumab in a Portuguese population
- 1 May 2017
- Published by Elsevier in International Immunopharmacology
- Vol. 46, 105-111
Long-term effectiveness and safety of natalizumab in a Portuguese population
- 1 November 2016
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 33, 73-78
Predictors of first-line treatment persistence in a Portuguese cohort of relapsing-remitting multiple sclerosis
- 1 November 2016
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 33, 73-78
Predictors of first-line treatment persistence in a Portuguese cohort of relapsing-remitting multiple sclerosis
- Open Access
- 5 April 2016
- Published by Hindawi Limited in Case Reports in Medicine
- Vol. 2016 (1) , 1-6
Encephalopathy Associated with Autoimmune Thyroid Disease: A Potentially Reversible Condition
Autoimmune thyroid disease may occasionally associate with unspecific neurological symptoms, which are more commonly insidious, include cognitive or behavioural symptoms, and may associate with tremor, myoclonus, or ataxia. We report a 61-year-old female patient who presented with chronic headache, insidious mood, and cognitive disturbance which evolved in a few months to dementia associated with exuberant limb myoclonus. Diagnostic workup revealed high anti-thyroid peroxidase antibody titers and an inflammatory CSF profile, and it was negative for other possible etiologies. Treatment with steroids induced significant improvement. The diagnosis of encephalopathy associated with autoimmune thyroid disease is still controversial given the fact that the clinical presentation and diagnostic workup are unspecific, the pathophysiology is still undetermined, and the diagnosis is mostly of exclusion. No direct correlation is found between anti-thyroid antibody titers and clinical presentation, and it is currently speculated that other still unrecognized antibodies may be responsible for this clinical entity. It is extremely important to recognize this entity because it is potentially treatable with immunotherapies. It is also increasingly recognized that clinical improvement with first-line treatment with steroids may be absent or incomplete, and other immunotherapies as immunosuppressants, intravenous immunoglobulin, or plasma exchange must be attempted in the clinical suspicion of EEAT.
- 5 April 2016
- Published by Hindawi Limited in Case Reports in Medicine
- Vol. 2016 (1) , 1-6
Open AccessEncephalopathy Associated with Autoimmune Thyroid Disease: A Potentially Reversible Condition
Autoimmune thyroid disease may occasionally associate with unspecific neurological symptoms, which are more commonly insidious, include cognitive or behavioural symptoms, and may associate with tremor, myoclonus, or ataxia. We report a 61-year-old female patient who presented with chronic headache, insidious mood, and cognitive disturbance which evolved in a few months to dementia associated with exuberant limb myoclonus. Diagnostic workup revealed high anti-thyroid peroxidase antibody titers and an inflammatory CSF profile, and it was negative for other possible etiologies. Treatment with steroids induced significant improvement. The diagnosis of encephalopathy associated with autoimmune thyroid disease is still controversial given the fact that the clinical presentation and diagnostic workup are unspecific, the pathophysiology is still undetermined, and the diagnosis is mostly of exclusion. No direct correlation is found between anti-thyroid antibody titers and clinical presentation, and it is currently speculated that other still unrecognized antibodies may be responsible for this clinical entity. It is extremely important to recognize this entity because it is potentially treatable with immunotherapies. It is also increasingly recognized that clinical improvement with first-line treatment with steroids may be absent or incomplete, and other immunotherapies as immunosuppressants, intravenous immunoglobulin, or plasma exchange must be attempted in the clinical suspicion of EEAT.
- 1 March 2016
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 6, 41-48
The effectiveness of fingolimod in a Portuguese real-world population
- 1 March 2016
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 6, 41-48
The effectiveness of fingolimod in a Portuguese real-world population